Welcome to Anagrammer Crossword Genius! Keep reading below to see if amif is an answer to any crossword puzzle or word game (Scrabble, Words With Friends etc). Scroll down to see all the info we have compiled on amif.
amif
Searching in Crosswords ...
The answer AMIF has 2 possible clue(s) in existing crosswords.
Searching in Word Games ...
The word AMIF is NOT valid in any word game. (Sorry, you cannot play AMIF in Scrabble, Words With Friends etc)
Searching in Dictionaries ...
Definitions of amif in various dictionaries:
AMIF - Amifampridine (pyridine-3,4-diamine, 3,4-diaminopyridine, 3,4-DAP) is used as a drug, predominantly in the treatment of a number of rare muscle dise...
Word Research / Anagrams and more ...
Keep reading for additional results and analysis below.
Possible Crossword Clues |
---|
"I __ you are": "Ready?" answer |
"I __ you are!" |
Last Seen in these Crosswords & Puzzles |
---|
Oct 9 2012 L.A. Times Daily |
Jun 15 2011 L.A. Times Daily |
Amif might refer to |
---|
Amifampridine (pyridine-3,4-diamine, 3,4-diaminopyridine, 3,4-DAP) is used as a drug, predominantly in the treatment of a number of rare muscle diseases. The free base form of the drug has been used to treat congenital myasthenic syndromes and Lambert–Eaton myasthenic syndrome (LEMS) through compassionate use programs since the 1990s and was recommended as a first line treatment for LEMS in 2006, using ad hoc forms of the drug, since there was no marketed form. * Around 2000 doctors at Assistance Publique – Hôpitaux de Paris created a phosphate salt form, which was developed through a series of companies ending with BioMarin Pharmaceutical which obtained European approval in 2009 under the trade name Firdapse, and which licensed the US rights to Catalyst Pharmaceuticals in 2012. As of January 2017, Catalyst and another US company, Jacobus Pharmaceuticals, which had been manufacturing the free base form and giving it away for free since the 1990s, were racing to obtain FDA approval for their versions first; the company that obtained the approval would have seven years of marketing exclusivity. * Amifampridine phosphate has orphan drug status in the EU for Lambert–Eaton myasthenic syndrome and Catalyst holds both an orphan designation and a breakthrough therapy designation in the US.. |